204 related articles for article (PubMed ID: 29022233)
21. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
22. The Role of Cardiovascular Imaging and Serum Biomarkers in Identifying Cardiotoxicity Related to Cancer Therapeutics.
Agha A; Zarifa A; Kim P; Iliescu C; Gladish G; Hassan S; Palaskas N; Durand JB; Lu Y; Lopez-Mattei J
Methodist Debakey Cardiovasc J; 2019; 15(4):258-266. PubMed ID: 31988686
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology
Breccia M; Carver JR; Szmit S; Jurczak W; Salvatorelli E; Minotti G
Semin Oncol; 2019 Dec; 46(6):403-407. PubMed ID: 31748121
[TBL] [Abstract][Full Text] [Related]
24. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
Onitilo AA; Engel JM; Stankowski RV; Liang H; Berg RL; Doi SA
Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
[TBL] [Abstract][Full Text] [Related]
25. Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States.
Craver C; Gayle J; Balu S; Buchner D
J Med Econ; 2011; 14(3):341-9. PubMed ID: 21542674
[TBL] [Abstract][Full Text] [Related]
26. Cardiotoxicity of Targeted Therapies in Children with Haematological Malignancies and Solid Tumors.
Bangeas A; Tragiannidis A
Anticancer Agents Med Chem; 2023; 23(15):1702-1709. PubMed ID: 37231721
[TBL] [Abstract][Full Text] [Related]
27. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond.
Di Lisi D; Madonna R; Zito C; Bronte E; Badalamenti G; Parrella P; Monte I; Tocchetti CG; Russo A; Novo G
Int J Cardiol; 2017 Jan; 227():11-17. PubMed ID: 27866063
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of heart diseases in patients with pulmonary embolism with and without peripheral venous thrombosis: findings from a cross-sectional survey.
Prandoni P; Pesavento R; Sørensen HT; Gennaro N; Dalla Valle F; Minotto I; Perina F; Pengo V; Pagnan A
Eur J Intern Med; 2009 Sep; 20(5):470-3. PubMed ID: 19712846
[TBL] [Abstract][Full Text] [Related]
29. The cardiotoxicity of anticancer agents.
Von Hoff DD; Rozencweig M; Piccart M
Semin Oncol; 1982 Mar; 9(1):23-33. PubMed ID: 7071608
[TBL] [Abstract][Full Text] [Related]
30. [Cardiotoxicity of chemotherapies].
Castel M; Despas F; Modesto A; Gales C; Honton B; Galinier M; Senard JM; Pathak A
Presse Med; 2013 Jan; 42(1):26-39. PubMed ID: 22727981
[TBL] [Abstract][Full Text] [Related]
31. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
Nelson-Veniard M; Thambo JB
Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
[TBL] [Abstract][Full Text] [Related]
32. Anticancer agents and cardiotoxicity.
Ng R; Better N; Green MD
Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
[TBL] [Abstract][Full Text] [Related]
33. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
34. Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
Escudier M; Cautela J; Malissen N; Ancedy Y; Orabona M; Pinto J; Monestier S; Grob JJ; Scemama U; Jacquier A; Lalevee N; Barraud J; Peyrol M; Laine M; Bonello L; Paganelli F; Cohen A; Barlesi F; Ederhy S; Thuny F
Circulation; 2017 Nov; 136(21):2085-2087. PubMed ID: 29158217
[No Abstract] [Full Text] [Related]
35. Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity.
Khan AA; Ashraf A; Singh R; Rahim A; Rostom W; Hussain M; Renner I; Collins NJ
Intern Med J; 2017 Jan; 47(1):104-109. PubMed ID: 27800661
[TBL] [Abstract][Full Text] [Related]
36. Cardiotoxicity of systemic agents used in breast cancer.
Ades F; Zardavas D; Pinto AC; Criscitiello C; Aftimos P; de Azambuja E
Breast; 2014 Aug; 23(4):317-28. PubMed ID: 24794210
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study.
Gunaldi M; Duman BB; Afsar CU; Paydas S; Erkisi M; Kara IO; Sahin B
J Oncol Pharm Pract; 2016 Apr; 22(2):242-7. PubMed ID: 25567518
[TBL] [Abstract][Full Text] [Related]
38. History of deep vein thrombosis is a discriminator for concomitant atrial fibrillation in pulmonary embolism.
Keller K; Prochaska JH; Coldewey M; Gobel S; Ullmann A; Jünger C; Lamparter H; Ariza L; Bickel C; Lauterbach M; Konstantinides S; Rostock T; Münzel T; Wild PS
Thromb Res; 2015 Nov; 136(5):899-906. PubMed ID: 26376038
[TBL] [Abstract][Full Text] [Related]
39. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
[TBL] [Abstract][Full Text] [Related]
40. [Cardiotoxicity of antineoplastic drugs].
Drzewoski J; Kasznicki J
Acta Haematol Pol; 1992; 23(2):79-86. PubMed ID: 1488864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
